Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib Combined With Lateral Ventricular Chemotherapy in Advanced NSCLC With Leptomeningeal Metastasis
NCT06332287Phase 2Recruiting
- Sponsor
- Affiliated Brain Hospital of Nanjing Medical University
- Start
- May 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trilaciclib in myelosuppression, sponsored by Affiliated Brain Hospital of Nanjing Medical University. Started May 2023; status: recruiting.
02
Drugs
trilaciclib
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NCT06332287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06332287.